Arnon R, Teitelbaum D
Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel.
Ther Immunol. 1994 Jan;1(1):65-70.
Recent advances in elucidating the activation and regulation of the autoimmune processes have provided new approaches for selective immunotherapy. Three different strategies are described: autoantigen-based therapy utilizing immunospecifically designed macromolecules and peptides, T-suppressor lines and clones, as well as antibodies specific to the antigen-MHC complex. These modalities, the efficacy of which has been demonstrated for experimental allergic encephalomyelitis, may be adapted to other experimental as well as human autoimmune diseases.
在阐明自身免疫过程的激活和调节方面的最新进展为选择性免疫治疗提供了新方法。本文描述了三种不同的策略:利用免疫特异性设计的大分子和肽进行基于自身抗原的治疗、T抑制细胞系和克隆,以及针对抗原-MHC复合物的特异性抗体。这些方法在实验性变应性脑脊髓炎中已证明有效,可能适用于其他实验性以及人类自身免疫性疾病。